載入...
PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders
Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descr...
Na minha lista:
| 發表在: | Ther Adv Neurol Disord |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6940603/ https://ncbi.nlm.nih.gov/pubmed/31921355 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286419895155 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|